Інсуліночутливі тканини та маркери інсулінорезистентності за цукрового діабету 2-го типу

О. П. Кіхтяк

doi:10.24026/1818-1384.2(31).2010.97239

Автор(и)

О. П. Кіхтяк Львівський національний медичний університет імені Данила Галицького, Львів, Ukraine

DOI:

https://doi.org/10.24026/1818-1384.2(31).2010.97239

Ключові слова:

insulin resistance, markers of insulin resistance, type 2 diabetes mellitus

Анотація

The article is dedicated to the problem of insulin sensitive tissues and insulin resistance markers in type 2 diabetes. Taking into account the substantial part of the bibliographical sources we arrived at the output about the possibility to classify the known markers of insulin resistance to the markers of the first and second order. In this case, for example, adiponectin, which is manufactured in the adipose tissue in an insufficient quantity under the conditions of adipose insulin resistance, it is considered as the specific marker of insulin resistance of the first order regarding to adipose tissue. At the same time adiponectin plays the role as the unspecific marker of insulin resistance of the second order concerning the liver and muscles where it is not synthesized. In our opinion, this separation of concepts will help to organize our knowledge into entire increased quantity of markers of insulin resistance in type 2 diabetes mellitus.

Біографія автора

О. П. Кіхтяк, Львівський національний медичний університет імені Данила Галицького, Львів

O. Kikhtyak

Посилання

Губський Ю.І. Біологічна хімія. — Київ; Тернопіль: Укрмед-книга, 2000. — 508 с.

Koch L., Munderlich T., Seibler J. et al. Central insulin action regulates peripheral glucose and fat metabolism in mice // J. Clin. Invest. — 2008. — Vol. 118. — P. 2132–2147. https://doi.org/10.1172/jci31073

Зайчик А.Ш., Чурилов Л.П. Основы патохимии. — СПб.: ЭЛБИ , 2000. — 688 с.

Маньковський Б.Н., Пхакадзе А.Г. Влияние периндоприла на содержание эндотелиальных факторов в крови больных сахарным диабетом 1 типа, осложненным нефропатией // Серце і судини. — 2008. — No1. — С. 60–65.

Bloomgarden Z.T. Insulin resistance concepts // Diabetes Care. — 2007. — Vol. 30, Suppl. 5. — P. 1320–1326. https://doi.org/10.2337/dc07-zb05

Muniyappa R., Montagnani M., Kon Koh K., and Quon M.J. Cardiovascular Actions of Insulin // Endocrine Reviews. — 2007. — Vol. 28 (5). — P. 463–491. https://doi.org/10.1210/er.2007-0006

Марчук Н.Ю., Сергієнко О.О. Роль інсулінової резистентності в розвитку синдрому полікістозних яєчників у дівчат-підлітків // Пробл. ендокринної патології. — 2005. — No3. — С. 72–86.

Weber M. The telmisartan Programme of Research tо show Telmisartan End-organ protection (PROTECTION) Programme // Journal of Hypertension. — 2003. — Vol. 21 Suppl. 6. — P. 37–46. https://doi.org/10.1097/00004872-200307006-00007

Natali A., Toschi E., Baldeweg S., Ciociaro D., Favilla S., Sacca L., Ferrannini E. Clustersng of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes // Diabetes. — 2006 — Vol. 55 (4). — Р. 1133–1140. https://doi.org/10.2337/diabetes.55.04.06.db05-1076

Kahn B.B., Flier J.S. Obesity and insulin resistance // J. Clin. Invest. — 2000. — No 106. — P. 473–481. https://doi.org/10.1172/jci10842

Hotamisligil G.S. The role of TNF alpha and TNF receptors in obesity and insulin resistance // J. Intern. Med. — 1999. — Vol. 245. — P. 621–625. https://doi.org/10.1046/j.1365-2796.1999.00490.x

Peraldi P., Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects // Mol. Cell. Biochem. — 1998. — Vol. 182. — P. 169–175. https://doi.org/10.1023/a:1006865715292

Кравчун Н.О. Фактор некрозу пухлин-α та цукровий діабет 2 типу // Пробл. ендокринної патології. — 2005. — No3. — С. 3–8.

Зайчик А.Ш., Чурилов Л.П. Общая патофизиология. — СПб.: ЭЛБИ-СПб., 2001. — 624 с.

Sethi G., Sung B., Aggarwal B.B. TNF: a master switch for inflammation to cancer // Front. Biosci. — 2008. — Vol. 1, No13 — P. 5094–5107. https://doi.org/10.2741/3066

Phielox E., Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function // Physiol. Behav. — 2008. — Vol. 94 (2). — P. 252–258. https://doi.org/10.1016/j.physbeh.2008.01.020

Griffin et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade // Diabetes. — 1999. — Vol. 48. — No 6. —P. 1270–1274. https://doi.org/10.2337/diabetes.48.6.1270

High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect / Zierath J.R., Houseknecht K.L., Gnudi L., Kahn B.B. // Diabetes. — 1997. — Vol. 46. — P. 215–223. https://doi.org/10.2337/diab.46.2.215

The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids / Borkman M. et al. // N. Eng. J. Med. — 1993. — Vol. 328. — P. 238–244. https://doi.org/10.1056/nejm199301283280404

De Feyter H.M., van den Broek N.M., Praet S.F. et al. Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction // Eur. J. Endocrinol. — 2008. — Vol. 158 (5). — P. 643–653. https://doi.org/10.1530/eje-07-0756

Adams J., Pratipanawatr T., Berria R. et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans // Diabetes. — 2004. — Vol. 53. — P. 25–31. https://doi.org/10.2337/diabetes.53.1.25

Yamauchi T, Kamon J, Ito Y. Cloning of adiponectin receptors that mediate antidiabetic metabolic effect // Nature. — 2003. — Vol. 423. — P. 762–769. https://doi.org/10.1038/nature01705

Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin — a key adipokine in the metabolic syndrome // Diabetes Obes. Metab. — 2006. — Vol. 8 (3). — P. 264–280. https://doi.org/10.1111/j.1463-1326.2005.00510.x

Lin-Lin L., Xiao-Long K., Xin-Jian R.,Ye W., Chang-Hui W., Lin H., Jun R., Xin L., Xin-Min M. Association between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes // Clinical and Experimental Pharmacology and Physiology. — 2007. — Vol. 34 (12): — P. 1287–1290. https://doi.org/10.1111/j.1440-1681.2007.04713.x

DeFronzo R.A., Tobin J.D., Andreas R. Glucose clamp technique: a method for quantifying insulin secretion and resistance // Am. J. Physiol. — 1979. — Vol. 237. — P. 214–223.

Пат. No8401 U Україна А 61 В 5/145; А 61 В 5/107, G 01 N 33/48. Спосіб оцінки інсулінорезистентності у хворих на цукровий діабет 2 типу /М.Ю.Горшунська, Ю.І.Караченцев, В.В.Полторак, О.М.Білецька /UA/.– No 20040907427; Заявл. 10.09.04; опубл. 15.08.05. // Промислова власність. — 2005. — Бюл. No 8.

Matheus D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man // Diabetologia. — 1985. — Vol. 28. — Р. 412–419. https://doi.org/10.1007/bf00280883

In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin/ Kim Y.B., Uotani S., Pierroz D.D. et al. // Endocrinology. — 2000. — Vol. 141. — P. 2328–2339. https://doi.org/10.1210/en.141.7.2328

Lang K., Ratke J. Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration // Cell Commun. Signal. — 2009. — Vol. 7(1). — Р. 27. https://doi.org/10.1186/1478-811x-7-27

Пат. No2201249 С2 Россия А 61 К 38/17, А 61 Р5/50, 3/10. Применение антагонистов лептина для лечения резистентности к инсулину при дабете ІІ типа / Эртль Й., Прайбиш Г., Мюллер Г. /DE/.– No 99107759/14; Заявл. 15.09.97; опубл. 27.03.03. // РСТ. — 2003.

Ogawa Y. et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin // Diabetes. — 1999. — Vol. 48. — P. 1822–1829. https://doi.org/10.2337/diabetes.48.9.1822

Joussen A.M., Doehmen S., Le, M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-α mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations // Molecular Vision. — 2009. — Vol. 15. — P. 1418–1428.

A nutrient-sensing pathway regulates leptin gene expression in muscle and fat / Wang J., Liu R., Hawkins M. et al. // Nature. — 1998. — Vol. 393. — P. 684–688. https://doi.org/10.1038/31474

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy / Shimomura I., Hammer R.E., Ikemoto S., et al. // Nature. — 1999. — Vol. 401. — P. 73–76. https://doi.org/10.1038/43448

Gavrilova O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice // J. Clin. Invest. — 2000. — Vol. 105. — P. 271–278. https://doi.org/10.1172/jci7901

Bray G.A. Autonomic and endocrine factors in the regulation of food intake // Brain Res. Bull. — 1985. — Vol. 14. — P. 505–510. https://doi.org/10.1016/0361-9230(85)90098-x

Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans // Curr Protein Pept. Sci. — 2009. — Vol. 10 (1). — P. 96–107. https://doi.org/10.2174/138920309787315239

Koch A., Gressner O.A., Edouard S., Tacke F., Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients // Critical Care. — 2009. — Vol. 13(3): R95. https://doi.org/10.1186/cc7925

Kim S.J., Nian C., McIntosh C.H. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes // Journal of Biological Chemistry. — 2007. — Vol. 282(47). — Р. 34139–34147. https://doi.org/10.1074/jbc.m704896200

Patti M.E., Kahn C.R. Lessons from transgenic and knockout animals about noninsulin-dependent diabetes mellitus // Trends Endocrinol. Metab. — 1996. — Vol. 7. — P. 311–319. https://doi.org/10.1016/s1043-2760(96)00154-3

Sattar N. Predicting type 2 diabetes: a role for novel parameters or simple prediction models? // Clinical laboratory. — 2005. — Vol. 29, No2. — P. 7–11.

Schaalan M., El-Abhar H.S., Barakat M., El-Denshary E.S. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride // J. Diabetes Complications — 2008. — Vol. 23. — P. 199-208. https://doi.org/10.1016/j.jdiacomp.2008.02.003

Rajala M.W.,Obici S., Scherer P.E. Adipose-derived resistin and gut-derived resistin-like molecular-β selectively impair insulin action on glucose production // J. Clin. Investigation. — 2003. — Vol. 111. — Р. 225–230. https://doi.org/10.1172/jci16521

Muniyappa R., Quon M.J. Insulin resistance in vascular endothelium // Curr. Opin. Investig. Drugs. — 2007. — Vol. 10(4). — Р. 523–530.

CDC. Centers for Disease Control and Prevention. 2006. Diabetes data and trends [online]. URL: http://www.cdc.gov/diabetes/statistics.

Andersen K., Pedersen B.K. The role of inflammation in vascular insulin resistance with focus on IL-6 // Horm. Metab. Res. — 2008. — Vol. 40(9). — Р. 635–639. https://doi.org/10.1055/s-0028-1083810

Capuzzi D., Freeman J. C-reactive protein and cardiovascular risk in the metabolic syndrome and type 2 diabetes: controversy and challenge // Clinical Diabetes. — 2007. — Vol. 25. — P. 16–22. https://doi.org/10.2337/diaclin.25.1.16

Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., Tracy R.P. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study // Diabetes. – 2001. — Vol. 50. — P. 2384–2389. https://doi.org/10.2337/diabetes.50.10.2384

Полторак В.В. Стандарт современных пероральных антидиабетических препаратов // Medicus Amicus. — 2005. — No5. — С. 16.

Maia-Fernandes T., Roncon-Albuquerque R.J., Leite-Moreira A.F. Cardiovascular actions of adiponectin: pathophysiologic implications // Rev. Port. Cardiol. — 2008. — Vol. 27 (11). — P. 1431–1449.

Kougias P., Chai H., Lin P.H, Yao Q., Lumsden A.B, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease // J. Surg. Res. — 2005. — Vol. 126 — Р. 121–129. https://doi.org/10.1016/j.jss.2004.12.023

Vecchione C., Aretini A., Maffei A., Marino G., Selvetella G., Poulet R., Trimarco V., Frati G., Lembo G. Cooperation between insulin and leptin in the modulation of vascular tone // Hypertension. — 2003 — Vol. 42. — Р. 166–170. https://doi.org/10.1161/01.hyp.0000082806.73530.68

Burnett M.S, Lee C.W, Kinnaird T.D, Stabile E., Durrani S., Dullum M.K. The potential role of resistin in atherogenesis // Atherosclerosis. — 2005. — Vol. 182 — Р. 241–248. https://doi.org/10.1016/j.atherosclerosis.2005.02.014

Lim S., Caballero E., Swakowski P., Logerfo F., Horton E., Veves A. Impairment in vascular reactivity and elevation of soluble intercellular adhesion molecule and vascular cell adhesion molecule precede the development of microalbuminuria and elevation of von Willebrand factor in individuals with type 2 diabetes // Diabetes. — 1999. — Vol. 48, Suppl. 1. — P. A142.

Beijers H.J., Ferreira I., Bravenboer B., Dekker J.M., Nijpels G., Heine R.J., Stehouwer C.D. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study // Diabetes Care. — 2009 — Vol. 32 (9). — Р. 1698–1703. https://doi.org/10.2337/dc08-1544

Stehouwer C.D., Smulders Y.M. Microalbuminuria and Risk for Cardiovascular Disease: Analysis of Potential Mechanisms // Journal of the American Society of Nephrology. — 2006. — Vol. 17. — Р. 2106–2111. https://doi.org/10.1681/asn.2005121288

Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis // Diabetologia. — 1989. — Vol. 32. — Р. 219–226. https://doi.org/10.1007/bf00285287

Rehm M., Zahler S., Lotsch M., Welsch U., Conzen P., Jakob M., Becker B.F. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed // Anesthesiology. — 2004. — Vol. 100. — Р. 2111–2113. https://doi.org/10.1097/00000542-200405000-00025

Малижев В.О., Анастасій Л.В., Ларін О.С., Неборачко М.В., Гирявенко О.Я. Ліпоцитокіни в ґенезі цукрового діабету 2-го типу // Клінічна ендокринологія і ендокринна хірургія. 2005. — No1 (10). — С. 3–25.